Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Longbio Pharma (Suzhou) Co's Gross Margin % or its related term are showing as below:
HKSE:01779's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.69 * Ranked among companies with meaningful Gross Margin % only.
Longbio Pharma (Suzhou) Co had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Longbio Pharma (Suzhou) Co (HKSE:01779) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Longbio Pharma (Suzhou) Co had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Longbio Pharma (Suzhou) Co Gross Margin % Related Terms
Longbio Pharma (Suzhou) Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Longbio Pharma (Suzhou) Co Gross Margin % Chart
Longbio Pharma (Suzhou) Co Annual Data
Trend
Dec24
Dec25
Gross Margin %
0.00
0.00
Longbio Pharma (Suzhou) Co Semi-Annual Data
Dec24
Dec25
Gross Margin %
0.00
0.00
HKSE:01779 vs VRTX, REGN, RVMD: Gross Margin % Comparison
For the Biotechnology subindustry, Longbio Pharma (Suzhou) Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Longbio Pharma (Suzhou) Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Longbio Pharma (Suzhou) Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Longbio Pharma (Suzhou) Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Longbio Pharma (Suzhou) Co (HKSE:01779) has a Gross Margin % of 0.00% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Longbio Pharma (Suzhou) Co and its competitors. According to the industry distribution chart, Longbio Pharma (Suzhou) Co ranks #999999 out of 735 companies in the Biotechnology industry.
Is Longbio Pharma (Suzhou) Co's Gross Margin % too high?
Longbio Pharma (Suzhou) Co's current Gross Margin % is 0.00%. Based on the distribution chart, Longbio Pharma (Suzhou) Co ranks #999999 out of 735 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Longbio Pharma (Suzhou) Co has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Longbio Pharma (Suzhou) Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Longbio Pharma (Suzhou) Co ranks #999999 out of 735 companies for Gross Margin %. This places Longbio Pharma (Suzhou) Co in the lower half of its industry. The industry median Gross Margin % is 60.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.69, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Longbio Pharma (Suzhou) Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Longbio Pharma (Suzhou) Co's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longbio Pharma (Suzhou) Co stock overvalued right now?
Longbio Pharma (Suzhou) Co (HKSE:01779) has a current Gross Margin % of 0.00%. The current Gross Margin % is 0.00%. Longbio Pharma (Suzhou) Co's overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Longbio Pharma (Suzhou) Co (HKSE:01779), the current Gross Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Longbio Pharma (Suzhou) Co Ltd is a clinical-stage biotechnology company. The company and its subsidiaries are principally engaged in the research, development, manufacture and commercialisation of pharmaceutical products in the People's Republic of China (the PRC). It has developed a comprehensive product pipeline for biologic treatments targeting rhinology, dermatology, respiratory, hematology, nephrology and other autoimmune diseases, targeting allergic and autoimmune diseases. Its pipeline includes LP-003, LP-00A, LP-005, LP-00C, and LP-00D.
10GF Score
Get the complete analysis for HKSE:01779
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01779 has been successfully added to your 
